Skip to main content
. 2014 Aug 7;6(10):1246–1262. doi: 10.15252/emmm.201404228

Figure 6. IGF2 reduces amyloid burden in 20-month-old Tg2576 mice.

Figure 6

  1. Representative hippocampal sections of sham- (Tg2576), AAV-IGF1- (Tg2576 IGF1) and AAV-IGF2- (Tg2576 IGF2) treated Tg2576 mice are shown (left panel). Scale bar = 100 μm. Amyloid burden quantification (right panel). Multiple extracellular deposits stained with 6E10 antiserum were detected in Tg2576 and Tg2576 IGF1 mice. Amyloid burden is reduced in the hippocampus of Tg2576 IGF2 mice (n = 3–5); however, no significant differences were found.
  2. Aβ42 and Aβ40 concentration determined by ELISA in the prefrontal and parietotemporal cortices (Cx) of Tg2576 mice and Tg2576 IGF1 mice showed similar values. Interestingly, Tg2576 IGF2 mice exhibited a significant reduction in Aβ42 (one-way ANOVA followed by Scheffe'spost hoc test,n = 7–8, *P = 0.050 Tg2576 versus Tg2576 IGF2 prefrontal Cx, **P = 0.007 Tg2576 versus Tg2576 IGF2 parietotemporal Cx, *P = 0.038 Tg2576 IGF1 versus Tg2576 IGF2 parietotemporal Cx) and Aβ40 (*P = 0.019 Tg2576 versus Tg2576 IGF2 prefrontal Cx, *P = 0.014 Tg2576 IGF1 versus Tg2576 IGF2 prefrontal Cx, **P = 0.003 Tg2576 versus Tg2576 IGF2 parietotemporal Cx, *P = 0.038 Tg2576 IGF1 versus Tg2576 IGF2 parietotemporal Cx) cortical levels. Data are the mean ± SEM.